20161122_mc2-portrait-02

Release your
full potential

Be active. Be free. Experience real-life
superior treatment with PADTM Technology based drugs.

ABOUT US

MC2 Therapeutics is a privately held emerging dermatology and eye care pharmaceutical company. Read more about MC2 Therapeutics.

Platform

Our PAD™ Technology is a new class of vehicle that enables development of new topical drugs with superior real-life performance. Read more about our platform.

Pipeline

Our current pipeline includes programs in major chronic topical diseases such as psoriasis, atopic dermatitis, pruritus and dry and sensitive skin and eyes. Read more about our pipeline.

LATEST NEWS

MC2 Therapeutics A/S announces completion of recruitment in US Phase 3 trial in Psoriasis Vulgaris

  • Topline results are expected in Q3 2018

Copenhagen, April 2nd, 2018 – MC2 Therapeutics A/S, a ...

READ FULL ARTICLE

MC2 Therapeutics A/S announces completion of recruitment in Phase 2 study in moderate-to-severe dry eye disease with MC2-03

  • Completion of patient recruitment meeting randomization target of 264 patients
  • Topline results are expected in 2018

 Copenhagen, ...

READ FULL ARTICLE

 

MC2 Therapeutics A/S announces first patient dosed in pivotal US Phase 3 trial in psoriasis vulgaris

  • First patient dosed in the pivotal Phase 3 trial assessing the safety and efficacy of ...

    READ FULL ARTICLE

MC2 Therapeutics A/S appoints Anders D. Hove and Paul L. Berns to the Board of Directors

Copenhagen, August, 2017 – MC2 Therapeutics A/S, a clinical-stage dermatology and eye care company, has ...

READ FULL ARTICLE

© mc2 therapeautics 2016